Dana V Rizk1, Arnold L Silva2, Pablo E Pergola3, Robert Toto4, David G Warnock1, Melanie P Chin5, Angie Goldsberry5, Megan O'Grady5, Colin J Meyer5, Peter A McCullough6. 1. Department of Medicine, Nephrology Division, University of Alabama at Birmingham, Birmingham, Alabama, USA. 2. Boise Kidney and Hypertension Institute, Meridian, Idaho, USA. 3. Renal Associates PA, San Antonio, Texas, USA. 4. Internal Medicine and Clinical Science, University of Texas Southwestern Medical Center, Dallas, Texas, USA. 5. Product Development, Reata Pharmaceuticals, Irving, Texas, USA. 6. Baylor Heart and Vascular Institute, Baylor Jack and Jane Hamilton Heart and Vascular Hospital, The Heart Hospital, Baylor University Medical Center, Dallas, Texas, USA, peteramccullough@gmail.com.
Abstract
BACKGROUND: Treatment with bardoxolone methyl (Bard) in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate with concurrent reductions in serum magnesium. We analyzed data from several trials to characterize reductions in magnesium with Bard. METHODS: BEACON randomized patients (n = 2,185) with type 2 diabetes (T2DM) and stage 4 chronic kidney disease (CKD) 1:1 to receive Bard (20 mg) orplacebo once daily. In a separate open-label study, magnesium levels from 24-hour urine and sublingual epithelial cell samples were analyzed in patients with stage 3b-4 CKD and T2DM administered 20 mg Bard for 56 consecutive days. RESULTS: BEACON patients randomized to Bard experienced significant reductions in serum magnesium from baseline relative to patients randomized to placebo (-0.17 mEq/L, 95% CI -0.18 to -0.60 mEq/L; p < 0.001). A separate study showed intracellular and urinary magnesium levels were unchanged with Bard treatment. CONCLUSIONS: Bard treatment results in significant decreases in serum magnesium that are not associated with changes in intracellular and urinary magnesium levels, indicating that magnesium decreases are not due to renal magnesium wasting or total body magnesium depletion. Importantly, the decreases in serum magnesium with Bard are not associated with adverse effects on QT interval. The Author(s). Published by S. Karger AG, Basel.
RCT Entities:
BACKGROUND: Treatment with bardoxolone methyl (Bard) in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate with concurrent reductions in serum magnesium. We analyzed data from several trials to characterize reductions in magnesium with Bard. METHODS:BEACON randomized patients (n = 2,185) with type 2 diabetes (T2DM) and stage 4 chronic kidney disease (CKD) 1:1 to receive Bard (20 mg) or placebo once daily. In a separate open-label study, magnesium levels from 24-hour urine and sublingual epithelial cell samples were analyzed in patients with stage 3b-4 CKD and T2DM administered 20 mg Bard for 56 consecutive days. RESULTS:BEACONpatients randomized to Bard experienced significant reductions in serum magnesium from baseline relative to patients randomized to placebo (-0.17 mEq/L, 95% CI -0.18 to -0.60 mEq/L; p < 0.001). A separate study showed intracellular and urinary magnesium levels were unchanged with Bard treatment. CONCLUSIONS:Bard treatment results in significant decreases in serum magnesium that are not associated with changes in intracellular and urinary magnesium levels, indicating that magnesium decreases are not due to renal magnesium wasting or total body magnesium depletion. Importantly, the decreases in serum magnesium with Bard are not associated with adverse effects on QT interval. The Author(s). Published by S. Karger AG, Basel.
Authors: Melanie P Chin; George L Bakris; Geoffrey A Block; Glenn M Chertow; Angie Goldsberry; Lesley A Inker; Hiddo J L Heerspink; Megan O'Grady; Pablo E Pergola; Christoph Wanner; David G Warnock; Colin J Meyer Journal: Am J Nephrol Date: 2018-01-18 Impact factor: 3.754
Authors: Albena T Dinkova-Kostova; Karen T Liby; Katherine K Stephenson; W David Holtzclaw; Xiangqun Gao; Nanjoo Suh; Charlotte Williams; Renee Risingsong; Tadashi Honda; Gordon W Gribble; Michael B Sporn; Paul Talalay Journal: Proc Natl Acad Sci U S A Date: 2005-03-14 Impact factor: 11.205
Authors: Pablo E Pergola; Melissa Krauth; J Warren Huff; Deborah A Ferguson; Stacey Ruiz; Colin J Meyer; David G Warnock Journal: Am J Nephrol Date: 2011-04-21 Impact factor: 3.754
Authors: Melinda S Yates; Masafumi Tauchi; Fumiki Katsuoka; Kathleen C Flanders; Karen T Liby; Tadashi Honda; Gordon W Gribble; Delinda A Johnson; Jeffrey A Johnson; Neal C Burton; Tomás R Guilarte; Masayuki Yamamoto; Michael B Sporn; Thomas W Kensler Journal: Mol Cancer Ther Date: 2007-01 Impact factor: 6.261
Authors: Dick de Zeeuw; Tadao Akizawa; Rajiv Agarwal; Paul Audhya; George L Bakris; Melanie Chin; Melissa Krauth; Hiddo J Lambers Heerspink; Colin J Meyer; John J McMurray; Hans-Henrik Parving; Pablo E Pergola; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; David G Warnock; Janet Wittes; Glenn M Chertow Journal: Am J Nephrol Date: 2013-02-28 Impact factor: 3.754
Authors: Anna-Liisa Levonen; Aimee Landar; Anup Ramachandran; Erin K Ceaser; Dale A Dickinson; Giuseppe Zanoni; Jason D Morrow; Victor M Darley-Usmar Journal: Biochem J Date: 2004-03-01 Impact factor: 3.857
Authors: Yanfeng Ding; Rhesa D Stidham; Ron Bumeister; Isaac Trevino; Ali Winters; Marc Sprouse; Min Ding; Deborah A Ferguson; Colin J Meyer; W Christian Wigley; Rong Ma Journal: Kidney Int Date: 2012-12-12 Impact factor: 10.612
Authors: Marguerite M Conley; Catherine M McFarlane; David W Johnson; Jaimon T Kelly; Katrina L Campbell; Helen L MacLaughlin Journal: Cochrane Database Syst Rev Date: 2021-03-30